Immunic, Inc., a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced the appointment of Tamara A. Seymour, MBA, as its Interim Chief Financial Officer, effective April 26, 2019. Ms. Seymour is a corporate finance veteran with three decades of experience in the biotech and life sciences industries.
MS linked to epigenetic changes in immune cells
Latest NewsEpigenetic changes in immune cells may provide the trigger of multiple sclerosis. Researchers have now identified MS-specific epigenetic biomarkers that change upon drug treatment.
Whitepaper Spotlight: Proactive Biomarker Planning to Optimize Clinical Trials
Sponsored PublicationsOncology drugs developed through a biomarker-guided precision medicine design are 38% more likely to be commercialized. But success relies on following a plan from the start — learn how in this free whitepaper
Lessons from a former poster child
OpinionWith partner Indivior exchanging a late-stage addiction programme for early-stage alternatives, 2019 did not start exceptionally well for Addex Therapeutics. But, the Swiss drug developer has shown the stamina to withstand far more serious setbacks in the past. For EuroBiotech, Addex’s CEO Tim Dyer recounts the company’s history and outlines its future.
Confo Therapeutics raise €30m in Series A financing
Latest NewsThe round was led by BioGeneration Ventures and Wellington Partners, with Fund+, Perceptive Advisors and existing investors Capricorn Venture Partners, MINTS, PMV, QBIC and V-Bio Ventures contributing.
LEA Jury announces the Winners of LEA 2019
Sponsored PublicationsResearchers report how body fat affects imune cells
Latest NewsUS scientists have found that the complex interactions between fat tissue and the immune system are mediated by interleukin 33 (IL-33).
European Lead Factory gets €36.5m support from IMI
Latest NewsThe European Lead Factory (ELF) – a drug discovery hub for validation new targets from academia and biotech SMEs – has again received project funding from the Innovative Medicine’s Initiative.
AstraZeneca set to licence 5 programmes from Transgène SA
Latest NewsAlentis Therapeutics debuts with CHF12.5m
Latest NewsLiver specialist Alentis Therapeutics AG has raised CHF12.5m in a Series A round co-led by BioMedPartners and BB Pureos Bioventures.
Immunic appoints Tamara A. Seymour as Interim CFO
AppointmentsImmunic, Inc., a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced the appointment of Tamara A. Seymour, MBA, as its Interim Chief Financial Officer, effective April 26, 2019. Ms. Seymour is a corporate finance veteran with three decades of experience in the biotech and life sciences industries.